Freenome, Inc. Common stock

Freenome, Inc. Common stock(FRNM)价格预测

$13.040

+0.329 (+2.52%)收盘时

价格预测

1-Day Price Prediction
+1.90%
1-Week Prediction
+7.44%
1-Month Prediction
—
2026 Prediction
—
2030 Prediction
—

在 App 中打开以解锁更长周期的预测。

Loading chart…

FRNM 相似图表分析预测

Alphio's FRNM stock price prediction model matches the current Freenome, Inc. Common stock tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $13.29 (+1.90%). The 1-week path is $14.01 (+7.44%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

该买入 Freenome, Inc. Common stock 股票吗?

Freenome, Inc. is a good buy right now due to its recent FDA approval for a colorectal cancer screening test, which has driven a 5% increase in stock price and indicates strong future revenue potential. The current price is $12.77, significantly below the analyst price target of $21, suggesting a potential upside of 64%. Additionally, the stock has shown a recent 5-day change of +8.68%, indicating positive momentum. However, a risk to consider is the negative net income reported for Q4 2025 at -740568.00 USD, which highlights ongoing financial challenges that could affect performance in the near term.

FRNM 股价于 Tuesday 收于 $13.04,此前上涨 +2.52%

Freenome, Inc. Common stock (FRNM) last closed at $13.04, gaining +2.52%. These facts feed the 1-day and 1-week FRNM price prediction above.

预测驱动因素

Freenome, Inc. Common stock(FRNM)的预测驱动因素综合了相似的图表形态、季节性与移动平均线。

Similar patterns

Positive

Bullish

Seasonality

Positive

Bullish

SMA 20

Negative

Bearish

SMA 200

Negative

Bearish

相似图表形态

近期走势与 FRNM 最接近的股票,按相似度排序。

FRNM 季节性分析

Loading chart…

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易